330 results about "Glycoprotein" patented technology

The application discloses a method for recovering active glycoprotein Patatin from potato starch processing waste juice, and belongs to the technical field of protein extraction. The method is characterized in that the active Patatin protein is efficiently separated by using the combination of ammonium sulfate fractionation precipitation, anion exchange chromatography, Con A affinity chromatography and gel chromatography, and the obtained Patatin protein retains the original protein structure and biological function activity. Compared with the prior art, the method has better separation purity and higher efficiency, and the obtained Patatin protein has complete protein higher structure and function activity, and has a better application scene.

The invention relates to the technical field of detection kits, in particular to a blood coagulation reaction linked lupus anticoagulant fluorescence detection kit and application thereof, the kit contains a screening-confirmation integrated reagent, a calibration product, a quality control product and an anticoagulation interference inhibitor; the integrated reagent is divided into a reagent A and a reagent B, the reagent A contains a buffer solution, recombinant snake venom thrombin, composite phospholipid, a fluorescent substrate and other components, and the reagent B contains prothrombin, calcium ions, high-concentration composite phospholipid and other components; the composite phospholipid system is formed according to a specific proportion and modifies beta2-glycoprotein I, the fluorescence enhancement-stabilization system is formed by matching a Schiff base compound with a stabilizer, the calibrator is a series of lupus anticoagulant standard substances, and the quality control substance comprises simulants with different concentrations and negative control. The anti-interference capability is high, and the influence of anti-coagulant drugs and enzyme source fluctuation is reduced; the signal amplification effect is obvious, the detection sensitivity is high and the reagent stability is good; the operation is simple and convenient, screening and confirmation are integrally completed, and a conventional fluorescence detector is adapted.

The invention belongs to the technical field of medicines, and discloses preparation and application of a paclitaxel-loaded liposome nano targeting preparation. The paclitaxel-entrapped nano-particles are prepared by adopting a film dispersion method, and micromolecular hyaluronic acid is entrapped on the surfaces of the lipid nano-particles by utilizing the charge effect. The bionic nano-drug provided by the invention is helpful for solving the problems of poor solubility, low bioavailability, high toxicity and the like of the anticancer drug paclitaxel. The hyaluronic acid has affinity with a glycoprotein CD44 receptor on the surface of a tumor cell, so that the nanoparticles are targeted and concentrated at a tumor part, the anti-tumor effect is improved, and the systemic toxicity of paclitaxel is reduced. The preparation process is simple, the cost is low, the stability is good, the repeatability is high, and the preparation method also has a better development prospect in the aspect of clinical application transformation.

The invention belongs to the technical field of bioengineering and application thereof, and particularly relates to a laver compound zymolyte as well as a preparation method and application thereof. The compound enzyme is prepared through a compound enzymolysis process of protease and laver polysaccharide enzyme. Compared with a traditional single proteolysis process, a composite enzymolysis process of adding the high-enzyme-activity laver polysaccharide enzyme effectively breaks a'polysaccharide-protein 'composite structure of laver cell walls, so that the viscosity of zymolyte is reduced, high laver liquefaction rate and high product yield are realized, and the release efficiency of nutritional active ingredients is remarkably improved; the product is rich in low-molecular-weight polypeptide and oligomeric porphyra polysaccharide. The obtained zymolyte shows the comprehensive effects of improving joint activity, inhibiting osteophyte formation, adjusting cartilage metabolism balance and relieving inflammatory response in an osteoarthritis mouse model, and osteoarthritis is effectively relieved. According to the invention, efficient release and utilization of nutritional active ingredients of the laver are realized, and powerful technical support is provided for developing high-valued products, such as health-care products and functional foods, which have the function of maintaining joint health.

The invention belongs to the field of biological prevention and control, and discloses an insect specific virus NLBV3 and application thereof in reducing transmission of rice odontodwarf virus of brown planthopper. The NLBV3 virus genome comprises three chains, the L chain encodes RNA dependent RNA polymerase (RdRP), the M chain encodes glycoprotein precursor (GP), the S chain encodes nucleoprotein (NP), and the nucleotide sequences are respectively shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; the application is realized by releasing the NLBV3-carrying brown planthopper population, and according to the screening and detection method of the NLBV3-carrying brown planthopper high-virus population provided by the invention, natural brown planthoppers can be effectively infected after the NLBV3-carrying brown planthopper high-virus population is released, the RRSV transmission capability of the brown planthoppers is reduced, and the virus is prevented from damaging rice production. The NLBV3 provided by the invention is an insect specific virus, is harmless to mammals, fishes and shrimps, natural enemy insects and pollination insects, and has the advantages of specific action object, environment friendliness and the like.

This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular, Bruton tyrosine kinase (“BTK”) inhibitors, for treatment of subjects with myelin oligodendrocyte glycoprotein antibody disease (MOGAD).

The present disclosure relates to polypeptides comprising an antigen fragment of the receptor binding domain (RBD) of coronavirus spike glycoprotein, protein nanostructures thereof, methods of manufacture thereof, and prophylactic and therapeutic uses thereof. In various aspects, the antigen fragment comprises a coronavirus subdomain 1 (SD1).

The present invention involves an engineered probiotic bacterium comprising a heterologous nucleic acid, where the heterologous nucleic acid comprises a nucleic acid sequence encoding an anti-spike glycoprotein nanobody of a coronavirus. In one embodiment, the bacterium is Escherichia coli Nissle 1917. In another embodiment, the anti-spike glycoprotein nanobody appears on the surface of the probiotic bacteria.

The invention belongs to the technical field of biological medicine, and provides an antibody targeting Gn glycoprotein on the surface of a severe fever with thrombocytopenia syndrome virus and application of the antibody. The antibodies N2C1 and N2D2 and the bispecific antibody obtained by modification based on the antibodies N2C1 and N2D2 provided by the invention can be specifically combined with Gn glycoprotein on the surface of the severe fever with thrombocytopenia syndrome virus, and show a strong neutralization protection effect in in-vitro cell and in-vivo animal experiments. Therefore, the N2C1 and N2D2 antibodies and the bispecific antibody obtained by modification can be used as drugs for preventing or treating severe fever with thrombocytopenia syndrome virus infection.

This invention relates to the field of biotechnology, specifically to a composition containing a multivalent pneumococcal polysaccharide-protein conjugate for the prevention of pneumococcal infection and VZV infection, its preparation method, and its application. The composition of this invention, comprising a multivalent pneumococcal polysaccharide-protein conjugate, uses an immunogenic VZV recombinant protein as the carrier protein; the pneumococcal polysaccharide is covalently linked to the VZV recombinant protein; the VZV recombinant protein is selected from gE protein, and its amino acid sequence is shown in SEQ ID NO: 3 or SEQ ID NO: 4. This invention addresses the prevalence of serotypes of pneumococcus unique to my country by creatively selecting serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. This results in a composition containing polyvalent pneumococcal polysaccharide-protein conjugates designed specifically for the prevalence of these serotypes in my country.

The application discloses a Sinonovacula constricta glycoprotein nano-enzyme Sc-NZ and a preparation method thereof, and particularly relates to the technical field of nano-enzymes. The Sinonovacula constricta glycoprotein nano-enzyme Sc-NZ is a cluster-shaped nanoparticle obtained by treating a product separated and purified from Sinonovacula constricta under ultrahigh pressure, and the particle size distribution is 30-50 nm. The preparation method comprises the following steps: taking soft body tissue of Sinonovacula constricta, homogenizing and defatting, centrifuging to collect the precipitate to obtain defatted powder, extracting the defatted powder by an alkali extraction and alcohol precipitation method, adjusting the pH to 4.0-5.0, collecting and drying the precipitate to obtain a crude glycoprotein; subjecting the crude glycoprotein to enzymolysis, and then sequentially subjecting the glycoprotein to anion exchange chromatography and gel filtration chromatography to collect an active component to obtain a Sinonovacula constricta natural glycoprotein; adding deionized water or a phosphate buffer to the Sinonovacula constricta natural glycoprotein to prepare a solution, and placing the solution in an ultrahigh pressure device to obtain the Sinonovacula constricta glycoprotein nano-enzyme Sc-NZ. The Sinonovacula constricta glycoprotein nano-enzyme Sc-NZ has the advantages of being prepared by green physical modification, high activity, high stability and multifunction.

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

The present invention provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified mRNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.

This invention relates to the field of biomedical technology, providing the application of glycoprotein tumor biomarkers in the preparation of cancer diagnostic reagents. The glycoprotein tumor biomarker is a CLU_N_291_HexNAc(4)Hex(5) site-specific glycosylation modification. This invention utilizes CLU_N_291_HexNAc(4)Hex(5) site-specific glycosylation modification as a pan-cancer biomarker, combining it with existing conventional tumor markers (CEA, CA19-9, CA50, CA242, CA72-4, CA125, CA15-3, AFP, SCC, CYFRA21-1, PROGRP, NSE, HE-4, or PSA) for early cancer screening, assessment, diagnosis, postoperative monitoring, and / or prognostic analysis, particularly for the diagnosis of pancreatic cancer, cholangiocarcinoma, gastric cancer, lung cancer, breast cancer, or ovarian cancer.

The invention provides a conversion method of rare ginsenoside Rg5. According to the method, through a vacuum permeation technology, gas in cell gaps of ginseng roots is removed in a vacuum environment, a permeation barrier of cell walls is weakened, a micro-channel is formed, and then a mixed solution of methanol and n-butyl alcohol is injected for primary extraction; after the normal pressure is recovered, the mixed solution can be driven by differential pressure to quickly fill a micro-channel and be better dissolved with the ginseng roots, a more efficient extraction environment is created, extraction is carried out under the low-temperature condition of 30-50 DEG C, thermal degradation of PPD can be effectively avoided, meanwhile, dissolution of impurities such as polysaccharide and protein is reduced, and the adverse effect of the impurities on subsequent conversion is reduced; finally, cellulose nanocrystals and a hydrochloric acid solution are added, on the basis that extraction is further promoted, protopanoxadiol saponin can be efficiently and directionally converted into rare ginsenoside Rg5, meanwhile, generation of an isomeride Rk1 of the rare ginsenoside Rg5 is reduced, and then the yield and purity of the Rg5 are remarkably improved.

The present invention relates to a method for recombinantly producing a glycoprotein composition comprising at least one glycoprotein comprising the step of cultivating a recombinant host cell which expresses the glycoprotein in a cultivation medium in a bioreactor having a pH measuring device positioned in the bioreactor and configured to be in physical contact with the cultivation medium, characterized in that (a) the cultivating is performed under sterile conditions, (b) the pH value measured with the pH measuring device differs by 0.05 units or less from the pH value of the cultivation medium, and (c) the relative content of at least one glycosylated variant in the glycoprotein composition has reduced batch-to-batch variability, compared to a method where the pH value measured by the pH measuring device differs by more than 0.05 units, preferably by more than 0.03 units, from the pH value in the cultivation medium, and thereby producing the glycoprotein composition. The present invention further relates to glycoprotein compositions produced by the method, and to the use of a method for carbon dioxide based pH calibration for improving batch-to-batch variability.

This invention discloses the application of reagents for detecting biomarker levels in the preparation of products for identifying obstructive sleep apnea. It relates to the field of biomarker technology and aims to overcome the shortcomings of existing technologies that rely on complex polysomnography (PSG) procedures, poor patient compliance, and a lack of effective molecular markers. The biomarkers used in this application consist of CD36 glycoprotein, 9-octadecenal, and protocatechuic acid 3-O-sulfate. This invention enables rapid and objective identification of obstructive sleep apnea by detecting the levels of the above biomarkers in plasma. The procedure is simple and well-accepted by patients. The combined use of multiple biomarkers can improve the accuracy and stability of the identification, making it suitable for screening or auxiliary diagnosis in medical institutions at different levels.

The utility model discloses a hemostasis assist device for vascular surgery, which relates to the technical field of medical instruments, and comprises a fixing mechanism, a vascular surgery hemostasis mechanism is arranged in the fixing mechanism, the vascular surgery hemostasis mechanism comprises a knob, and the bottom of the knob is fixedly connected with a threaded column. According to the hemostasis mechanism for the vascular surgery department, during hemostasis, the periphery of a wound can be heated through the heating block across the replacement pad, the temperature of the periphery of the wound reaches 37-42 DEG C, activation of platelets can be accelerated to a certain extent at the temperature, energy metabolism of the platelets is accelerated within the temperature range, and the blood circulation is accelerated. The increase of the concentration of calcium ions in the blood platelets is an important signal of platelet activation, and the increased concentration of the calcium ions can promote the activation of glycoprotein receptors on platelet membranes, so that the binding capacity of the blood platelets and fibrinogen is enhanced, the aggregation of the blood platelets is accelerated, and the hemostasis speed is accelerated.

The present disclosure provides a polyribonucleotide encoding a polypeptide comprising a viral antigen from herpes simplex virus-2 (HSV-2); for example, the viral antigens comprise an extracellular domain of HSV-2 glycoprotein B. The polyribonucleotides can be formulated as RNA compositions that can be used to induce an anti-HSV immune response in a subject.

This invention discloses the application of American ginseng glycoprotein extract in the preparation of drugs for treating alcoholic liver disease, belonging to the field of biomedical technology. This invention verifies that TD can significantly reduce serum ALT, AST, and TG levels in ALD mice, effectively reducing liver damage and lipid accumulation; inhibit NLRP3 protein expression and its downstream targets, effectively alleviating liver inflammation and pyroptosis; and improve intestinal flora imbalance in ALD mice. American ginseng glycoprotein extract has multi-target protective effects against alcoholic liver disease, reducing alcohol-induced liver tissue inflammation and oxidative stress damage. It has a mild composition and high safety profile, and can synergistically exert effects in liver protection, anti-inflammation, and antioxidation, making it suitable for adjunctive intervention and long-term management of alcoholic liver disease, providing a natural, mild, and effective protective pathway for alcoholic liver damage.

This disclosure provides a recombinant hepatitis C virus glycoprotein comprising heterodimers of E1 and E2 glycoproteins having at least 60% homology with SEQ ID No. 1, engineered furin protease cleavage sites, and hydrophilic amino acid linkers, wherein the E1 and E2 glycoproteins partially or completely lack their respective transmembrane domains. This document further provides nucleic acids encoding the recombinant hepatitis C virus glycoprotein, nanoparticle conjugates comprising the recombinant hepatitis C virus glycoprotein, and compositions comprising the recombinant hepatitis C virus glycoprotein, the nucleic acid, or the nanoparticle conjugate. Applications of the recombinant hepatitis C virus glycoprotein or compositions comprising the glycoprotein are also envisioned.

The present application provides a kind of oil composition, containing monounsaturated fatty acid, polyunsaturated fatty acid, monounsaturated fatty acid is omega-9 fatty acid;Polyunsaturated acid is the mixture of omega-6 fatty acid and omega-3 fatty acid.The present application can repair and resist aging, all-purpose skin care, increase epidermal thickness, enhance barrier, anti-inflammatory soothing, anti-wrinkle firming, soothing repair red, nourish skin, and can be applied to sensitive skin, can inhibit LPS-induced HaCaT cell IL-6 secretion, increase the thickness of 3D skin model epidermis layer, and can promote the expression of silk aggregate protein (FLG), ceramide synthase 3 (CerS3), desmoglein core glycoprotein (DSG1) which has important role for skin barrier function, indicating that it can alleviate the inflammatory response produced by LPS stimulation HaCaT cell and has enhanced skin barrier function.

The invention discloses a liquid food salty taste enhancer based on hydrophilic colloid and a preparation method thereof, and the method comprises six steps of Arabic gum pretreatment, Arabic gum component primary separation, Arabic gum component secondary separation, freeze drying treatment, glycoprotein-glycan powder preparation and plastic packaging. The obtained salty taste enhancer has a high salty taste enhancing effect, and the purposes of enhancing the salty taste strength, reducing the salt content and balancing the food quality can be achieved only through an extremely small adding amount. According to the application, the Arabic gum is taken as a raw material, the components of the Arabic gum are optimized to regulate and control the salty taste enhancing effect, and a novel high-efficiency and low-dosage salty taste perception accelerant which can be used for healthy low-salt food is provided for people.

The present invention concerns a recombinant SARS-CoV-2 S glycoprotein trimer stabilized in a conformation that is anterior to the post-fusion conformation, as well as a proteoliposome comprising such a recombinant trimer and a vaccine based on such a proteoliposome. The invention also relates to a method of treating or preventing a SARS-CoV-2 infection in a subject using such a vaccine.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

Provided is a modified regulatory T cell capable of recognizing cells of the liver, capable of treating and / or preventing transplant rejection or immune-mediated damage, and capable of promoting regeneration of cells of the liver.SOLUTION: The present invention provides engineered regulatory T cells (Tregs) comprising a chimeric antigen receptor (CAR), wherein said CAR comprises an antigen recognition domain that specifically binds to the asialoglycoprotein receptor (ASGR). The invention also provides a method of promoting liver tissue repair and / or regeneration in a subject, said method comprising administering to said subject a modified Treg comprising a CAR, or a pharmaceutical composition comprising said modified Treg, wherein said CAR comprises a liver-specific antigen recognition domain.SELECTED DRAWING: None

The disclosure provides methods for determining the presence of coronavirus neutralizing antibodies in a sample as well as associated compositions and kits. The methods of the disclosure use recombinant vesicular stomatitis virus (VSV) particles, wherein the VSV glycoprotein (G) is replaced by a coronavirus spike(S) glycoprotein or a fragment or a derivative thereof. In a specific embodiment, the S glycoprotein is derived from Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) and the methods are used for determining the presence of SARS-CoV-2 neutralizing antibodies.

The invention discloses a black fungus quality analysis method based on infrared spectroscopy, and belongs to the field of black fungus quality analys.The method comprises the steps that infrared spectroscopy collection and data analysis are conducted on black fungus samples of different producing areas and different batches, and the corresponding relation between spectral characteristics and main components of black fungus is established; therefore, rapid, lossless and multi-dimensional detection and evaluation of components such as auricularia auricula polysaccharides, proteins, lipids, calcium oxalate crystals and the like are realized. Compared with a traditional method depending on sensory indexes, physicochemical indexes and single chemical analysis, the method has the advantages that the detection time is short, complex sample pretreatment is not needed, and more comprehensive and objective quality information can be provided.